Transgender men on hormone therapy have a high incidence of PFD (94.1%) and experience a greater occurrence of urinary symptoms (86.7%).

Summary

An analysis of 68 transgender people taking testosterone found a high prevalence of pelvic floor dysfunction (PFD), with 94.1% of participants reporting symptoms. The most common issues were urinary symptoms, affecting a significant portion of the study group. This highlights the need for further research and awareness of PFD among transgender men undergoing hormone therapy. The document does not specify how long the participants were on hormones.